CM
BCAX

Caption Management’s Bicara Therapeutics BCAX Stock Holding History

Caption Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$891K Sell
30,000
-14,600
-33% -$326K ﹤0.01% 1169
2026
Q1 		$887K Hold
44,600
– – 0.01% 1057
2025
Q4 		$751K Buy
+44,600
New +$762K 0.01% 1152

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caption Management's BCAX Position: Q2 2026 in Review

Caption Management sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 23,000 shares — an estimated $513K sold.

Caption Management first reported a position in BCAX in Q4 2025 and held it in 2 quarters. The position peaked at $457K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Caption Management reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 23,000 Bicara Therapeutics shares in Q2 2026, an estimated $513K.
  • Caption Management first reported a position in Bicara Therapeutics in Q4 2025 and held it in 2 quarters.
  • Caption Management's Bicara Therapeutics position peaked at $457K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.